glucagon receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
== Critical considerations and actual trends == Some major drawbacks of the common protocols for the in-gel digestion are the extended time needed and the multiple processing steps, making the method error-prone with respect to contaminations (especially keratin). These disadvantages were largely removed by the development of optimised protocols and specialised reaction tubes. More severe than the difficulties with handling are losses of material while processing the samples. The mass spectrometric protein analysis is often performed at the limit of detection, so even small losses can dictate success or failure of the whole analysis. These losses are due to washout during different processing steps, adsorption to the surface of reaction tubes and pipette tips, incomplete extraction of peptides from the gel and/or bad ionisation of single peptides in the mass spectrometer. Depending on the physicochemical properties of the peptides, losses can vary between 15 and 50%. Due to the inherent heterogeneity of the peptides, up to now, a universally valid solution for this major drawback of the method has not been found.
He also served as a member of the executive committee of the American Society for Testing and Materials (A.S.T.M.) Committee E-19 on Chromatography (1966–1973); as a foreign member of the executive committee of the (British) Chromatographic Society (1992–1997); and as an executive committee member of the Chromatography Subdivision of the Division of Analytical Chemistry of the American Chemical Society (A.C.S.).
== Mission parameters == Mass: 3,570 kg (7,870 lb) Perigee (insertion): 165.8 km (103.0 mi; 89.5 nmi) Apogee (insertion): 293.7 km (182.5 mi; 158.6 nmi) Period: 88.94 min Inclination: 32.53° Perigee (last orbit): 150 km (93 mi; 81 nmi) Apogee (last orbit): 232.8 km (144.7 mi; 125.7 nmi)
Sources: en.wikipedia.org
== Toxicity == Though few people come in contact with mendelevium, the International Commission on Radiological Protection has set annual exposure limits for the most stable isotope. For mendelevium-258, the ingestion limit was set at 9×105 becquerels (1 Bq = 1 decay per second). Given the half-life of this isotope, this is only 2.48 ng (nanograms). The inhalation limit is at 6000 Bq or 16.5 pg (picograms).
=== Fungal aminopeptidases === Fungi, particularly species like Aspergillus oryzae and Aspergillus sojae, produce aminopeptidases that have applications in the food industry as debittering agents. These enzymes are also of interest for their potential biotechnological applications. For example, leucine aminopeptidase (LAP) from Aspergillus species has been found to be thermostable and could theoretically be used to control the degree of hydrolysis and flavor development in a wide range of substances.
In many periodic tables, the f-block is shifted one element to the right, so that lanthanum and actinium become d-block elements in group 3, and Ce–Lu and Th–Lr form the f-block. Thus the d-block is split into two very uneven portions. This is a holdover from early mistaken measurements of electron configurations; modern measurements are more consistent with the form with lutetium and lawrencium in group 3, and with La–Yb and Ac–No as the f-block. The 4f shell is completely filled at ytterbium, and for that reason Lev Landau and Evgeny Lifshitz in 1948 considered it incorrect to group lutetium as an f-block element. They did not yet take the step of removing lanthanum from the d-block as well, but Jun Kondō realized in 1963 that lanthanum's low-temperature superconductivity implied the activity of its 4f shell. In 1965, David C. Hamilton linked this observation to its position in the periodic table, and argued that the f-block should be composed of the elements La–Yb and Ac–No. Since then, physical, chemical, and electronic evidence has supported this assignment. The issue was brought to wide attention by William B. Jensen in 1982, and the reassignment of lutetium and lawrencium to group 3 was supported by IUPAC reports dating from 1988 (when the 1–18 group numbers were recommended) and 2021. The variation nonetheless still exists because most textbook writers are not aware of the issue.
In the Middle Ages, based on a mistranslation from the Arabic term for bitumen, it was thought that mummies possessed healing properties. As a result, it became common practice to grind Egyptian mummies into a powder to be sold and used as medicine. Francis Bacon and Robert Boyle recommended them for healing bruises and preventing bleeding. When actual mummies became unavailable, the sun-desiccated corpses of criminals, slaves and people who committed suicide were substituted by some merchants. The trade in mummies seems to have been disapproved of by Turkish authorities who ruled Egypt – several Egyptians were imprisoned for boiling mummies to make oil in 1424. However, mummies were in high demand in Europe and it was possible to buy them for the right amount of money. John Snaderson, an English tradesman who visited Egypt in the 16th century shipped six hundred pounds of mummy back to England. The practice developed into a wide-scale business that flourished until the late 16th century. As recently as two centuries ago, mummies were still believed to have medicinal properties to stop bleeding, and were sold as pharmaceuticals in powdered form as in mellified man. Artists also made use of Egyptian mummies; a brownish pigment known as mummy brown, based on mummia (sometimes called alternatively caput mortuum, Latin for death's head), which was originally obtained by grinding human and animal Egyptian mummies.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.